Cambridge-based clinical-stage biopharmaceutical company Spero Therapeutics, Inc. is focusing its efforts on the challenging area of multi-drug resistant bacterial infections and rare diseases. The company's current product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating complicated urinary tract infections in adults, SPR206, a direct-acting, IV-administered agent designed to tackle MDR Gram-negative bacterial infections in hospital, and SPR720, a novel oral antibiotic that could be used as a treatment for non-tuberculous mycobacterial pulmonary disease. Tebipenem HBr is supported by a license agreement with Meiji Seika Pharma Co., Everest Medicines has licensed the development, manufacture, and commercialization rights for SPR206 in China, South Korea, and Southeast Asian countries, whilst Bill & Melinda Gates Medical Research Institute is partnering on the development of SPR720 to fight lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement has been signed with Vertex Pharmaceuticals Incorporated for patents relating to SPR719, an active metabolite of SPR720. Spero Therapeutics, Inc. was established in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics's ticker is SPRO
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Spero Therapeutics
It is sperotherapeutics.com
Spero Therapeutics is in the Healthcare sector
Spero Therapeutics is in the Biotechnology industry
The following five companies are Spero Therapeutics's industry peers: